Evidence map›Paper›PMID 36186673›Full record

ArticleClinical Medicine Insights. Oncology2022

Preoperative Absolute Lymphocyte Count to Carcinoembryonic Antigen Ratio Is a Superior Predictor of Survival in Stage I to III Colorectal Cancer.

Yue Zhou, Fei Cheng, Zihao Zhang, Jia Xiang, Tianhui Xue, Qianwen Ye, Bing Yan

Abstract read
In one paragraph

Article in Clinical Medicine Insights. Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yue ZhouDepartment of Clinical Laboratory, Hainan Hospital of Chinese PLA General Hospital, Sanya, P.R. China.
Fei ChengDepartment of Clinical Laboratory, Hainan Hospital of Chinese PLA General Hospital, Sanya, P.R. China.
Zihao ZhangDepartment of Clinical Laboratory, Hainan Hospital of Chinese PLA General Hospital, Sanya, P.R. China.
Jia XiangDepartment of Oncology, Hainan Hospital of Chinese PLA General Hospital, Sanya, P.R. China.
Tianhui XueDepartment of Oncology, Hainan Hospital of Chinese PLA General Hospital, Sanya, P.R. China.
Qianwen YeDepartment of Oncology, Hainan Hospital of Chinese PLA General Hospital, Sanya, P.R. China.
Bing YanDepartment of Oncology, Hainan Hospital of Chinese PLA General Hospital, Sanya, P.R. China.ORCID https://orcid.org/0000-0001-5430-4761

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Preoperative absolute lymphocyte count (ALC) and carcinoembryonic antigen (CEA) are useful prognostic indicators in colorectal cancer (CRC); however, the role of the ALC-to-CEA ratio (LCR) has been less addressed. Methods: A total of 189 stage I to III CRC patients who underwent radical resection were enrolled retrospectively. The significance of the LCR in predicting disease-free survival (DFS) and overall survival (OS) was calculated and compared with other markers based on ALC. The DFS and OS differences among the low- and high-LCR subgroups and risk factors for the outcome were estimated by Kaplan-Meier analysis and the Cox proportional hazards model, respectively. Results: Taking 0.28 as the cutoff point, the LCR has a sensitivity and a specificity of 75.60% and 77.00%, respectively, in predicting OS. The prognostic efficacy of LCR was significantly superior to that of other markers based on ALC for predicting DFS and OS. A total of 34.92% (66/189) of patients displayed a low LCR (<0.28), and these patients were more likely to present poor cell differentiation ( Conclusions: The LCR is a superior predictor of survival in stage I to III CRC, and patients with a low LCR have an inferior outcome; however, additional studies are required to validate its prognostic role.

Indexed as

carcinoembryonic antigenColorectal cancerdisease-free survivallymphocyte countsoverall survival

Identifiers

PMID36186673
PMCPMC9515526

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.